Sionna scraps genetic disorder drug program after trial setback; shares tank

• SION-719 failed to significantly lower chloride levels in patients' sweat during the 14-day study, missing its primary endpoint for cystic fibrosis treatment effectiveness
• The company cited variations in patient test results and differences in Trikafta levels as potential factors that may have influenced the trial outcome
• Sionna is separately developing a two-drug combination (SION-451 with SION-2222) for cystic fibrosis, with an early-stage study meeting safety goals, though the company is reviewing next steps for that program

Summary: Sionna Therapeutics Terminates Drug Program After Trial Failure

Key Development:

Sionna Therapeutics announced Monday it is discontinuing development of SION-719, an experimental treatment for cystic fibrosis, following disappointing mid-stage trial results. The company's shares plummeted on the news.

Trial Details:

• SION-719 was tested as an add-on therapy to Vertex Pharmaceuticals' Trikafta in 15 adults with cystic fibrosis
• The drug failed to significantly reduce sweat chloride levels, a critical biomarker for cystic fibrosis treatment efficacy
• The 14-day study showed the drug was generally well-tolerated with mild to moderate side effects and no serious adverse events reported

Company Response:

CEO Mike Cloonan expressed disappointment over the "unexpected results." Sionna cited patient variability in test results and differences in Trikafta levels as potential factors affecting trial outcomes. The company is reviewing the data before determining next steps.

Pipeline Impact:

Sionna is separately developing a two-drug combination therapy (SION-451 and SION-2222) for cystic fibrosis. An early-stage study in healthy volunteers met safety and drug-exposure goals, though the company is reassessing its development strategy for this program.

Market Context:

Cystic fibrosis is a genetic disorder causing thick mucus buildup in lungs, leading to breathing difficulties and recurring infections. Vertex Pharmaceuticals' Trikafta currently represents the standard of care, making it a challenging benchmark for add-on therapies to demonstrate incremental benefit.

The termination represents a significant setback for Sionna's development pipeline and raises questions about the viability of its remaining cystic fibrosis programs.